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Abstract 
INTRODUCTION: The detection of estrogen, progesterone and HER-2 neu receptors on the surface of the 
tumour cell is a significant prognostic factor, alone or in combination. The presence or absence of receptors on 
the surface of the tumour cell is associated with the conditional gene expression in the tumour cell itself. Based on 
these genetically determined expressions of the tumour cell, five molecular subtypes of breast cancer have been 
classified on the St. Gallen International Expert Consensus in 2011 that can be immunohistochemically detected, 
with each subtype manifesting certain prognosis and aggression. 
AIM: Analyzing the presentation of molecular subtypes of breast cancer that are immunohistochemically detected 
in surgically treated patients at the Clinic for Thoracic and Vascular Surgery. 
MATERIAL AND METHODS: We used the international classification on molecular subtypes of breast cancer 
which divides them into: Luminal A (ER+ and/or PR+, HER-2 negative, Ki-67 < 14%), Luminal B with HER-2 
negative (ER+ and/or PR+, HER-2 negative, Ki-67 ≥ 14%), Luminal B with HER-2 positive (ER+ and/or PR+, 
HER-2+, any Ki-67), HER-2 enriched (ER-, PR-, HER-2+), and basal-like (triple negative) (ER-, PR-, HER-2 
negative, CK5/6+ and/or EGFR+). A total of 290 patients, surgically treated for breast cancer, were analysed 
during 2014. 
RESULTS: In our analysis, we found that Luminal A was present in 77 (26.55%) patients, Luminal B HER-2 
negative was present in 91 (31.38%) patients, Luminal B HER-2 positive was present in 70 (24.14%) patients, 
HER-2 enriched was present in 25 (8.62%) patients and basal-like (or triple negative) was present in 27 (9.31%) 
patients. 
CONCLUSION: Detecting the subtype of breast cancer is important for evaluating the prognosis of the disease, 
but also for determining and providing an adequate therapy. Therefore, determining the subtype of breast cancer 
is necessary for the routine histopathological assay. 
 
 
 
 
 
 
 
 
Introduction 
 
Breast cancer is the most frequent malignant 
disease among women worldwide, but also in the 
Republic of Macedonia [1] [2] [3] [4]. Also, breast 
cancer is the leading cause of cancer mortality [1] [2] 
[3] [4]. Today, many factors are listed as most 
important ones for determining the prognosis of breast 
cancer, like tumour size, histologic subtype, tumour 
grade, lymphovascular invasion of tumour cells and 
axillary lymph node status. However, the presence of 
hormonal receptors (estrogen and progesterone) on 
the surface of the tumour cell, the presence of HER-2 
neu receptor and other factors have been added to 
this list in the last twenty years [5]. Also, the biological 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2                                                                                                                                                                                                    https://www.id-press.eu/mjms/index 
 
potential for proliferation and dividing was routinely 
examined, represented as Ki67 value. Today, every 
patient that is surgically treated undergoes routine 
examination with standard macroscopic and 
microscopic histological analysis, TNM staging, 
staging by immunohistochemical recognition of 
estrogen receptors (ER), progesterone receptors 
(PR), the presence of HER-2 neu receptors, and the 
prognostic value of Ki67 [6]. Each of these 
parameters, alone or in combination, determines the 
biology and aggression of the tumour, but also gives 
us the opportunity to treat the given type of breast 
cancer properly. The combination of these parameters 
gives us the opportunity to determine the genetic 
subtype of breast cancer. According to the new 
classification system for breast cancer subtypes 
presented in St. Gallen, which we use, breast cancer 
is divided in Luminal A, Luminal B with HER2 
negative, Luminal B with HER2 positive, HER2 
enriched and basal-like (triple negative) [7]. 
Analyzing the presence of breast cancer 
subtypes in our materials, and comparing the results 
with other studies to see if some subtypes in our 
materials differ from other studies published before, 
also, determining if the subtypes and the clinical stage 
are somehow correlated. 
 
 
Material and Methods 
 
A total of 290 patients, who were surgically 
treated for breast cancer at the University Clinic for 
Thoracic Surgery, Skopje, Republic of Macedonia 
were analysed during 2014, with complete history, 
using all parameters.  
All cases underwent standard histological 
examination, including macroscopic and microscopic 
analysis with standard H&E staining. 
Immunohistochemical staining for ER, PgR, HER-2 
and Ki-67 were performed on sections of formalin-
fixed paraffin-embedded tissue from the primary 
tumours. Pathohistological tests were conducted in 
three accredited laboratories (two in the Institute of 
Pathology at the Medical Faculty in Skopje and one in 
a private laboratory). 
 Upon microwave-pretreated in citric acid 
(10 mM), monoclonal mouse antibody to ER, PgR, 
HER-2 or Ki-67 was applied for 30 min at room 
temperature using the following dilutions: anti-ER-
1 : 100, anti-PgR-1 : 80 (DAKO laboratories, UK); pre-
diluted anti-HER-2 (Hercept test, DAKO Laboratories, 
UK); anti-Ki-67-1 : 200 (DAKO Laboratories, UK). 
Upon three rinses in Tris-buffered saline (TBS) and 
incubation with the secondary antibody, positive 
brown staining was detected using standard avidin 
and biotinylated horseradish peroxidase (ABC) 
technique with 3, 3′-diaminobenzidine (DAB) as the 
chromogen. Slides were then counterstained in 
Mayer's haematoxylin for 10 seconds, dehydrated in 
graded alcohol, mounted and scored. 
 Positive and negative controls were 
performed with each stain, and surgical specimens 
from the same patient were stained on the same run. 
For persistence of estrogen and progesterone 
receptors were included all results with +, ++ or +++ 
on immunohistochemical examination. For 
persistence of HER-2 receptors were included all 
patients with +++ result on immunohistochemical 
analysis.  
In cases where ICT determined HER-2 neu 
positive status + or ++ patients underwent FISH 
analyses for defining the HER2-neu gene 
amplification status. 
Pathohistological, grading and staging criteria 
for breast cancer were determined by using criteria 
from American Join Committee (AJC) and TNM 
classification according to UICC (International Union 
for Cancer Control) [8] [9]. According to the new 
classification system for breast cancer subtypes 
presented in St. Gallen, which we use, breast cancer 
is divided in Luminal A, Luminal B with HER2 
negative, Luminal B with HER2 positive, HER2 
enriched and basal-like (triple negative) [7]. 
Statistical analysis was performed with 
Statistica 7 by using standard descriptive analyses, 
2
 
test and ANOVA test for analysing the variance. 
 
 
Results 
 
Patient's age was ranged between 18-90 
years, an average of 57.6 years. The mean size of a 
primary tumour was 30.27 + 18.3 mm. Axillary lymph 
nodes metastases were detected in 59% of the 
patients. 
We used the new St. Gallen classification 
system for defining breast cancer subtypes into five 
groups. (Table 1) [7]. 
Table 1: Definition of subtypes of breast cancer- St. Gallen 
classification 
Subtypes of breast cancer Er and Pr Her-2 Ki67 
Luminal a Er + and/or pr + Her-2- Ki67<14% 
Luminal b with her-2 negative Er+ and/or pr+ Her-2- Ki-67≥14% 
Luminal b with her-2 positive Er + and / or pr + Her-2 + Any ki-67 
Her-2 enriched Er-, pr- Her-2 + Any ki-67 
Basal-like (triple negative) Er-, pr- Her-2- Ck5/6 + and/or egfr + 
 
Subtypes are characterised based on tumour 
size, lymph nodes involvement, histologic subtype, the 
persistence of receptors, lymphovascular invasion, the 
presence of p53 and stage, and are presented in 
Tables 2-9. 
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Table 2: Characteristics of subtypes according to the age of 
the patients  
 LA LB-Her2- LB-Her2+ HER2+ TN Total  
Number 
(%) 
77 
(26.55%) 
91 
(31.38%) 
70 
(24.14%) 
25 
(8.62%) 
27 
(9.31%) 
290 
(100%) 
 
Mean age 
(y) 
57.83 58.83 57.64 552.72 56.74 57.56 X=57.6 y 
 
From our analysis, we found that: 
- Luminal A was present in 77 (26.55%),  
- Luminal B HER2 negative was present in 91 
(31.38%), 
- Luminal B HER2 positive was present in 70 
(24.14%),  
Table 3: Characteristics of subtypes according to the size of 
the tumour 
 LA LB-Her2- LB-Her2+ HER2+ TN Total p 
Tumour size        
Tis 6 2 3 2 0 13 (4.48%)  
T1a 11 11 12 1 2 37 (12.76%)  
T1b 8 3 3 1 1 16 (5.51%)  
T1c 9 17 12 7 3 48 (16.55%)  
T2 37 43 36 9 18 143 (49.31%)  
T3 3 6 2 2 2 15 (5.17%)  
T4 3 9 2 3 1 18 (6.19%) 1.0 
Number 77 91 70 25 27 290  
 
- HER2 enriched was present in 25 (8.62%) 
and 
- Basal-like (or triple negative) was present in 
27 (9.31%) patients. 
Table 4: Characteristics of subtypes according to the size of a 
tumour and lymph nodes involvement 
 LA LB-Her2- LB-Her2+ HER2+ TN Total p 
Mean tumor 
size (mm) 
29.3 31.8 27.2 31.3 35.0 X = 30.3  
Axillary LN 
status 
       
N0 41 28 26 14 10 119 
(41.03%) 
 
N+ 36 63 44 11 17 171 
(58.97%) 
0.99 
Number 77 91 70 25 27 290  
 
 
Discussion 
 
Breast carcinoma is a heterogeneous disease 
with several clinical and histopathological 
presentations, which present different gene 
expressions in several subtypes and molecular 
profiles, hence giving different predictive and 
prognostic characteristics for the patients. Gene 
expressions were analysed using DNA microarrays. 
Due to the cost of DNA analysis, the use of 
immunohistochemical analysis of markers, which have 
been used as surrogate tools for defining subtypes of 
breast cancer, was generally accepted. According to 
the 2011 St. Gallen consensus conference, 5 
subtypes of breast cancer were defined using the 
presence of receptors on the surface of the tumour 
cell, and the measuring values of Ki67 [7] [10] [11]. 
Table 5: Characteristics of subtypes according to histologic 
subtype 
 LA LB-Her2- LB-Her2+ HER2+ TN Total p 
Histologic 
subtype 
       
Ductal 59 76 58 20 24 237(81.72%)  
Lobular 11 6 7 2 1 27 (9.31%)  
Other 7 9 5 3 2 26 (8.97%) 0.99 
Number 77 91 70 25 27 290  
 
Many of the prognostic factors predicting the 
disease are very well-known, and so is their biological 
mode of action and how they work to spread the 
disease in the body. Estrogen receptors are on the 
surface of the tumour cell, so once estrogen binds 
with the estrogen receptors, it activates many 
processes in the cell and stimulates growth and cell 
division. Hence, estrogen stimulates tumour growth. 
Giving drugs that block estrogen receptors or drugs 
that block estrogen synthesis can stop the tumour 
growth.  
Table 6: Characteristics of subtypes according to histological 
grade 
 LA LB-Her2- LB-Her2+ HER2+ TN Total p 
Histologic 
grade 
       
1 6 3 4 0 3 16 (5.52%)  
2 58 56 49 19 20 202 (69.65%)  
3 13 32 17 6 4 72 (24.82%) 0.99 
Number 77 91 70 25 27 290  
The same situation applies to the presence of 
HER-2 neu receptors. HER-2 is a membrane tyrosine 
kinase and oncogene that is overexpressed and gene 
amplified in about 20% of the breast cancer cases. 
When activated it provides the cell with potent 
proliferative and anti-apoptosis signals, and it is the 
major driver of tumour development and progression 
of breast cancer. 
Table 7: Characteristics of subtypes according to the 
persistence of receptors (estrogen, progesterone and HER2 
neu) 
 LA LB-Her2- LB-Her2+ HER2+ TN Total p 
Estrogen 
receptors 
       
Positive 72 86 57 0 0 215 (74.14%)  
Negative 5 5 13 25 27 75 (25.86%) 1.0 
Number 77 91 70 25 27 290  
        
Progesterone 
receptors 
       
Positive 73 88 65 0 0 226 (77.93%)  
Negative 4 3 5 25 27 64 (22.07%) 1.0 
Number 77 91 70 25 27 290  
        
Her 2 neu 
receptors 
       
Positive 0 0 70 25 0 95 (32.76%)  
Negative 77 91 0 0 27 195 (67.24%) 1.0 
Number 77 91 70 25 27 290  
Overexpression will activate many pathways 
in the cell, resulting in uncontrolled cell growth and 
division, causing the tumour to grow uncontrollably. 
Target drug delivery, monoclonal antibody 
trastuzumab (Herceptin), will block these receptors, 
and control a tumour. Moreover, giving 
chemotherapeutics that interact with the rapidly 
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dividing cells will control a tumour. Ki67 is the factor 
that shows the proliferative activity of tumour cells. 
Ki67 correlates with the S phase of the cell cycle and 
with the mitotic activity. A normal breast cell has a 
proliferative activity of 3% (3% of the cells are in the 
dividing stage).  
Table 8: Characteristics of subtypes according to the 
persistence of p53, LVI (lymphovascular invasion) and values 
of Ki67 
 LA LB-Her2- LB-Her2+ HER2+ TN Total p 
P53        
Positive 27 49 29 11 15 131(45.18%)  
Negative 50 42 41 14 12 159 (54.82%) 0.99 
Number 77 91 70 25 27 290  
        
LVI        
Positive 22 45 27 11 12 117 (40.34%)  
Negative 55 46 43 14 15 173 (59.65%) 0.99 
Number 77 91 70 25 27 290  
        
Ki67        
Up to 14% 77 0 36 4 9 126 (43.44%)  
More than 
14% 
0 91 34 21 18 164 (56.56%) 1.0 
Number 77 91 70 25 27 290  
 
Higher Ki67 index correlates with young age, 
larger tumours, positive lymph nodes, negative 
estrogen receptors and positive HER-2 receptors [12]. 
An activity that is higher than 14%, at some studies 
large than 20%, shows aggressive tumours with poor 
prognosis and shorter overall survival [10] [11] [12]. 
Table 9: Characteristics of subtypes according to the stage of 
the disease 
 LA LB-Her2- LB-Her2+ HER2+ TN Total p 
Stage        
0 1 2 0 0 0 3 ( 1.03%)  
IA 16 6 11 7 3 43 (14.83%)  
IB 3 4 2 0 0 9 ( 3.10%)  
IIA 26 26 18 6 7 83 (28.62%)  
IIB 13 15 18 6 8 60 (20.69%)  
IIIA 7 17 13 2 4 43 (14.83%)  
IIIB 4 5 2 2 2 15 ( 5.17%)  
IIIC 7 16 6 2 3 34 (11.72%) 1. 
Number 77 91 70 25 27 290  
 
Knowing the subtype: 
- we can predict the biology of a tumour 
and its future behaviour; 
- we can predict the prognosis of the 
disease; 
- we can plan a targeted therapy for 
some of the subtypes. 
Knowing the prevalence of subtypes in one 
population can help plan a general therapeutic 
approach [16]. 
Some authors define 4 subtypes: Luminal A, 
Luminal B, HER-2 enriched and basal cell (triple 
negative) (Valejos, Carey), other authors define 6 
subtypes: Luminal A, Luminal B, HER2+, basal-like 
(triple negative), normal breast cell-like and Claudin-
low (Eroles), but the most frequently used 
classification encompasses 5 subtypes [7] [13] [14] 
[17]. In practice, breast subtypes are defined by 
detecting the presence of estrogen, progesterone and 
HER-2 neu receptors on the surface of the malignant 
cell using immunohistochemical assays. Knowing that 
the presence or absence of receptors on the surface 
of breast cancer cell is conditioned by gene mutations 
and overexpression, subtypes can also be detected 
by assessing the gene expression. This is why the 
term genotype of breast cancer is cited in the 
literature. 
The most frequent type is Luminal A which is 
found in 50-72% of the patients with breast cancer. 
Patients with this type of cancer have the best 
prognosis, i.e. low proliferative index, good 
differentiation, with the lowest risk of local recurrence 
and relapse [13] [15] [16] [17] [18]. 
However, there are different values registered 
in literature regarding this subtype: Italy 34%, Saudi 
Arabia 3.9%, China 65.3% and Japan 71% [24] [25] 
[26] [27]. 
The suggested therapy for these patients is 
third-generation aromatase inhibitors in 
postmenopausal women, selective estrogen receptor 
modulators (like tamoxifen) and selective estrogen 
receptor modulators (like fulverstone) [13] [15] [16] 
[17] [18]. 
In our examination, Luminal A type was 
detected only in 26.55% of the patients. 
Luminal B subtype is characterised with 
positive estrogen receptors, with positive or negative 
HER2 receptors, with a higher Ki-67 value of over 
14%, which in both types of Luminal B gives worse 
prognosis than Luminal A subtype.  
Luminal B type is found in 10-20% of the 
patients with breast cancer, and in our examination, 
the HER-2 negative was detected in 31.38% and 
HER-2 positive in 24.14 % of the patients. Literature 
references are as follows: Italy 36%, Egypt 24.6% [24] 
[28]. This shows that most of the tumours in our group 
are aggressive. Luminal B subtype is much more 
aggressive than the Luminal A subtype and is 
characterised by poor differentiation, more frequent 
bone metastases and with a worse prognosis. Many 
authors suggest that patients in this subtype are 
younger patients with bigger tumours, with positive 
nodal status and higher N stage [16]. Given the 
presence of larger tumours and the advanced stage of 
the disease, Luminal B findings are more frequent in 
our study. Regarding patient's age, there was no 
difference found between Luminal A and Luminal B 
types; however, in our study, Luminal B prevailed in 
older patients [13] [15] [16] [17] [18]. 
The suggested treatment is with tamoxifen, 
but also chemotherapy in neoadjuvant and adjuvant 
courses [13] [15] [16] [17] [18]. 
HER-2 enriched subtype is found in 15-20% 
of the patients. In our group, it was detected in 8.62% 
of the patients. This subtype is characterized by high 
proliferative index and poor differentiation in most of 
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the patients, and p53 mutations are very often 
detected. This is a very aggressive type of a tumour, 
with only 12% of the patients surviving 10 years [13] 
[14] [16] [17] [18]. 
The suggested treatment requires target 
HER-2 therapy with monoclonal antigen trastuzumab 
(Herceptin) which changes the prognosis. This 
therapy needs to be combined with chemotherapy in 
the neoadjuvant and adjuvant protocol. Treatment 
with trastuzumab in combination with DM1 is also 
possible [13] [15] [16] [17] [18]. 
Subtype Basal-like (triple negative) is 
characterised with larger tumours, poor differentiation, 
high mitotic index and tumour necrosis. This type is 
found in 10-20% of the patients. A similar subgroup of 
this subtype is Claudin-low, where the only 
differentiation is the difference in EGFR and the fact 
that this type is found in 12-14% of the patients. Both 
subgroups have bad prognosis, poor differentiation 
and high mitotic index. Very often metastases in 
visceral organs, lungs and CNS are detected. This 
type has the worst prognosis, and very often the 
disease relapses in the first three years, and p53 
mutations are very often detected [13] [14] [15] [16] 
[17] [18] [34]. 
In our study, the triple negative was detected 
in 9.31% of the cases. 
The suggested therapy is chemotherapy, but 
also PARP inhibitors (poly ADP ribosome polymerase 
inhibitors) like olaparib in detected BRCA1 or BRCA2 
mutations [14] [15]. 
The normal breast cell-like subtype that is 
defined by some authors is found in 5-10% of the 
patients. This type doesn't respond to neoadjuvant 
therapy, only to adjuvant chemotherapy protocol. 
Often, it is well-differentiated with low proliferation 
index and is characterised by median overall survival 
[14]. 
We registered the difference in frequencies 
among our subgroups and those cited in the literature. 
This explains the heterogeneity of breast cancer 
across the world. It is cited in the literature that some 
subtypes are more frequent in certain races (triple 
negative is more frequent in African-American 
women) [13] [19]. Knowing the prevalence of subtypes 
in one population, we can plan a general therapeutic 
approach [16]. 
There is no significant difference in age 
regarding subgroups of breast cancer, patients range 
between 52,72 and 58,83 years, except in Luminal B 
HER negative and HER enriched subgroups (P = 
0.0255). Patient’s age in subgroups of breast cancer 
is shown in Figure 1. 
The mean size of tumours in different 
subgroups ranges between 27.18 and 35 mm. The 
biggest tumour diameter was found in the triple 
negative subgroup, but there were no significant 
differences in the whole group, and also between 
subgroups. The same situation applies to the tumour 
diameter defined as T stage with no difference in the 
position between subgroups. 
High differentiation values (G3-low 
differentiation) of the malignant cell in Luminal B 
subtype of breast cancer were detected in 35.16% of 
the patients. In triple negative subtype, G3 was 
detected only in 14.8% of the patients, which is 
contrary to the case results reported in many studies 
in the literature [13] [14] [17]. 
 
Figure 1: Patients age according to subgroups of breast cancer 
 
Regarding lymphovascular invasion, the 
highest values were detected in Luminal B HER-2 
negative, i.e. in 49.45% of the patients, which 
suggested invasive and aggressive subtype of breast 
cancer, with a tendency for lymphatic spread and 
higher frequency of axillary lymph node involvement 
(69.23%). The relatively low values of lymphovascular 
invasion in triple negative subtype are interesting to 
comment (44.44%), with low axillary lymph node 
involvement (62.96%), which correlates with the 
findings in the literature. Knowing the aggression of 
triple negative subtype of breast cancer, we can 
conclude that the spreading of malignant cells follows 
other pathways other than lymphatic [14] [17] [30] [31] 
[32] [33] [34] [35]. 
Regarding the values of Ki67, the factor that 
suggests the proliferative activity of the tumour, its 
aggression and biology, values higher than 14% were 
detected in Luminal B HER negative subtype (in all 
patients), but also in HER-2 enriched and triple-
negative subtypes. On the contrary, no values higher 
than 14% were detected in Luminal A subtype, which 
suggests that this subtype is less aggressive [13] [14] 
[15] [16] [17] [18].  
The patterns of distribution of cells positive for 
estrogen, progesterone and HER-2 neu receptors 
were significantly different in subgroups, which is 
normal because we know that these receptors are 
main factors for defining the different subtypes of 
breast cancer [7] [14]. 
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Knowing the subtype of breast cancer, in 
addition to the histological type and TNM stage, can 
suggest further prognosis of the disease, detect the 
spreading and find where metastases can appear 
later, but can also suggest further therapeutic 
approach [15]. 
Also knowing that all factors that determine 
breast cancer subtypes can be evaluated from core 
biopsy materials before starting treatment, some 
subtypes (the more aggressive ones) can be treated 
with adequate drugs in neoadjuvant protocol [14]. 
In conclusion, detecting the subtype of breast 
cancer is important for disease prognosis, but also for 
determining and providing an adequate therapy. 
Hence, the molecular subtype of breast cancer needs 
to be determined in a routine histopathological assay. 
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